Liovel is a fixed dose combination tablet of Nesina (alogliptin) and Actos (pioglitazone HCL).
Nesina, which is a member of the dipeptidyl peptidase IV (DPP-4) inhibitor class, is developed by Furiex in collaboration with Takeda’s wholly-owned subsidiary Takeda San Diego.
Under an agreement between the companies, Takeda is responsible to pay royalty payments on Liovel sales to Furex.
Furiex president and chief medical officer June Almenoff said this launch adds to Furiex’s revenue stream and confirms their strategy of partnering drug candidates in return for royalty payments.